ReviewCurrent cardiology reports2026
Potential Role of Circulating Biomarkers in Peripheral Artery Disease.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo review evidence on the role of circulating biomarkers associated with lower extremity peripheral artery disease (PAD) and adverse outcomes in people with PAD. RECENT
findingsThe ankle-brachial index (ABI) is a non-invasive, guideline-recommended test to diagnose PAD. Circulating biomarkers may offer additional insight into early detection of PAD and risk stratification of adverse events in people with PAD. Observational studies show that higher levels of inflammatory biomarkers (such as C-reactive protein, interleukin-6, soluble intracellular adhesion molecule-1), thrombosis biomarkers (such as D-dimer, fibrinogen), cardiac biomarkers (such as troponin, N-terminal pro-brain natriuretic peptide, lipoprotein A), and omic markers are associated with increased risk of developing PAD. Some of these markers are also associated with severity and adverse outcomes in people with PAD. While association studies have shown links between circulating biomarkers and PAD, no single biomarker or combination of markers is currently guideline-recommended for routine clinical use in diagnosis or management of PAD due to absence of clinical trial data showing that circulating biomarkers definitively improve outcomes in PAD. The current state of biomarkers in PAD suggests that further study is needed to determine whether biomarker-guided therapy will improve diagnosis or clinical outcomes for people at risk and people with PAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.